Skip to content

Pertuzumab fixed serum PK contexts

Four fixed two-compartment pertuzumab contexts with explicitly attributed coefficient conventions, central mg infusions, apparent distribution and physical exposure accounting.

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer ↗

Cancer Chemotherapy and Pharmacology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the two pertuzumab parameter contexts alter accumulation?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Fixed constructed PK context A

Fixed two-compartment serum PK context with explicit central mg infusions, supplied constant covariates and coefficient convention, and physical exposure accounting.

0–84 day

Scenario details

Fixed constructed PK context A

Fixed two-compartment serum PK context with explicit central mg infusions, supplied constant covariates and coefficient convention, and physical exposure accounting.

Readouts

Pertuzumab concentration · ug/mL
Retained physical state or serum concentration readout
Exposure (AUC) · ug*day/mL
Retained physical state or serum concentration readout
Eliminated · mg
Integrated central elimination
Accounted drug · mg
Delivered-input drug budget

Study purpose

  • How do the model's key biological readouts change under fixed constructed pk context a?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
84 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Four fixed two-compartment pertuzumab contexts with explicitly attributed coefficient conventions, central mg infusions, apparent distribution and physical exposure accounting.

Four fixed two-compartment pertuzumab contexts with explicitly attributed coefficient conventions, central mg infusions, apparent distribution and physical exposure accounting.

Model details

13 parameters · 5 states · 5 equations · 36 derived outputs

Classification & API access
Therapeutic
Pertuzumab
Modality
Monoclonal antibody
Target
HER2 / ERBB2
Disease / scope
HER2-positive early breast cancer
ParameterDefaultUnitDescription
Systemic clearanceCL_L_day0.235L/dayFixed conditional PK coordinate; not an editable, fitting or population parameter.
Intercompartmental clearanceQ_L_day0.534L/dayFixed conditional PK coordinate; not an editable, fitting or population parameter.
Central distribution volumeVc_L3.11LFixed conditional PK coordinate; not an editable, fitting or population parameter.
Peripheral distribution volumeVp_L2.46LFixed conditional PK coordinate; not an editable, fitting or population parameter.
Serum albuminalbumin_g_dL4.4g/dLFixed conditional PK coordinate; not an editable, fitting or population parameter.
Albumin reference galbumin_ref_g_dL3.9g/dLFixed conditional PK coordinate; not an editable, fitting or population parameter.
Lean body weightlean_body_weight_kg44.6kgFixed conditional PK coordinate; not an editable, fitting or population parameter.
Lean body weight referencelean_body_weight_ref_kg49.2kgSupplied constructed exponent/reference convention; fixed source-Table1 contexts override the four exponents and LBW normalization explicitly.
Nonclinical concentration referencetarget_ctrough_ug_mL20µg/mLFixed conditional PK coordinate; not an editable, fitting or population parameter.
Typical albumin clearancetheta_albumin_CL-1.0631197196508155—Supplied constructed exponent/reference convention; fixed source-Table1 contexts override the four exponents and LBW normalization explicitly.
Typical lbw clearancetheta_lbw_CL0.5218678893275605—Supplied constructed exponent/reference convention; fixed source-Table1 contexts override the four exponents and LBW normalization explicitly.
Typical lbw central distribution volumetheta_lbw_Vc0.7548032438936657—Supplied constructed exponent/reference convention; fixed source-Table1 contexts override the four exponents and LBW normalization explicitly.
Typical lbw peripheral distribution volumetheta_lbw_Vp0.8426696822233762—Supplied constructed exponent/reference convention; fixed source-Table1 contexts override the four exponents and LBW normalization explicitly.

Related models

T-DM1 and T-DXd conditional intact-ADC pharmacokineticsEculizumab fixed PK and authored response diagnosticsNivolumab exposure and tumor-size dynamicsZenocutuzumab PK and tumor-growth dynamics

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics